Covid in India: The COVID-19 vaccines developed by Zydus Cadila for children above the age of 12 are likely to get emergency use permission by the Drugs Controller General of India (DCGI), India’s drug regulator.
Trials have been conducted on adults as well as children over 12 years of age and the data has been submitted to the DCGI. If the panel is satisfied with the results, permission will be granted for emergency use this week.
The regulator’s subject expert committee (SEC) will examine the data submitted by Cadila. According to a report in The Times of India, if the SEC finds the vaccine company’s Phase III data satisfactory, then emergency access for the vaccine may be allowed this week.
An official said that if Zydus Cadila gets emergency clearance from DCGI, the supply of the vaccine is expected to start by August-September. “Preliminary evaluation of the application submitted by the company is underway and we have forwarded it to the SEC for further consideration. With the SEC meeting in the coming week, company representatives will also be asked to make a presentation,” an official said. said.
Earlier, NK Arora of Zydus Cadila had said that vaccination of children above 12 years would start from September. But if DCGI gives nod, the company will start the process in August.
ZyCoV-D is a three-dose, intradermal vaccine that is applied using the PharmaJet needle-free system. It can be stored at 2-8 °C but has shown good stability at a temperature of 25 °C for at least 3 months
According to the World Health Organization, DNA vaccination involves stimulating the immune system in a specific way to prevent or ameliorate diseases caused by infectious agents.
.